文章：

胶质母细胞瘤纳米医学中的血脑屏障攻克：策略、临床进展与新兴挑战

Blood–Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges

原文发布日期：27 September 2024

DOI: 10.3390/cancers16193300

类型: Article

开放获取: 是

英文摘要：

Glioblastoma (GBM) is a prevalent type of malignancy within the central nervous system (CNS) that is associated with a poor prognosis. The standard treatment for GBM includes the surgical resection of the tumor, followed by radiotherapy and chemotherapy; yet, despite these interventions, overall treatment outcomes remain suboptimal. The blood–brain barrier (BBB), which plays a crucial role in maintaining the stability of brain tissue under normal physiological conditions of the CNS, also poses a significant obstacle to the effective delivery of therapeutic agents to GBMs. Recent preclinical studies have demonstrated that nanomedicine delivery systems (NDDSs) offer promising results, demonstrating both effective GBM targeting and safety, thereby presenting a potential solution for targeted drug delivery. In this review, we first explore the various strategies employed in preclinical studies to overcome the BBB for drug delivery. Subsequently, the results of the clinical translation of NDDSs are summarized, highlighting the progress made. Finally, we discuss potential strategies for advancing the development of NDDSs and accelerating their translational research through well-designed clinical trials in GBM therapy.

摘要翻译： 

胶质母细胞瘤（GBM）是中枢神经系统中最常见的恶性肿瘤之一，预后较差。标准治疗方案包括手术切除肿瘤，随后进行放疗和化疗；然而，尽管采取了这些干预措施，总体治疗效果仍不理想。血脑屏障（BBB）在维持中枢神经系统正常生理状态下脑组织稳定性方面起着关键作用，同时也严重阻碍了治疗药物向GBM的有效递送。近期的临床前研究表明，纳米药物递送系统（NDDSs）展现出良好的应用前景，既能有效靶向GBM又具有安全性，从而为靶向药物递送提供了潜在的解决方案。本综述首先探讨了临床前研究中为克服血脑屏障实现药物递送所采用的各种策略；随后总结了NDDSs的临床转化成果，重点突出了已取得的进展；最后，我们讨论了通过精心设计的临床试验推动NDDSs发展并加速其在GBM治疗中转化研究的潜在策略。

原文链接：

Blood–Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges